---
schema_version: "secwatch.filing_event.v1"
accession: "0000015847-26-000009"
form_type: "8-K"
ticker: "BUKS"
cik: "0000015847"
company_name: "BUTLER NATIONAL CORP"
filed_at: "2026-06-01T16:41:32+00:00"
generated_at: "2026-06-01T16:42:13.838539+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# CEO Christopher Reedy discloses ongoing cancer treatment; remains in role

## Summary
- CEO Christopher Reedy informed employees of new medical treatment following Mayo Clinic consultations; he has continued follow-ups since 2019 cancer diagnosis.
- Reedy will continue as CEO and remain actively engaged with operations, leadership team, and Board.
- Executive Chairman Jeffrey D. Yowell and Lead Independent Director Joseph P. Daly expressed full Board support for Reedy.
- Treatment may periodically require time away from office; executive leadership team and Board will support ongoing operations.

## SEC filing metadata
- accession: 0000015847-26-000009
- form_type: 8-K
- ticker: BUKS
- cik: 0000015847
- company_name: BUTLER NATIONAL CORP
- filed_at: 2026-06-01T16:41:32+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/15847/000001584726000009/0000015847-26-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/15847/000001584726000009/buks-20260601.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000015847-26-000009
- JSON: https://secwatch.observer/filing/0000015847-26-000009.json
- Plain text: https://secwatch.observer/filing/0000015847-26-000009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.